What’s Trending?

Thanks to recent "turmoil" at the company, Leerink Partners analyst Geoffrey Porges has called Alexion “one of the rare, once or twice per decade, activist investment situations in the biopharmaceutical industry.” And one prominent activist reportedly wants to take advantage of the opportunity. [...]
Fri, Dec 08, 2017
Source FiercePharma
The FDA dealt Novartis' Sandoz unit a blow last summer when it issued a complete response letter for the company's biosimilar version of Amgen's blockbuster drug Neulasta. Today the Swiss drug giant took a big step forward to making a second pass at approval. [...]
Fri, Dec 08, 2017
Source FiercePharma
Johnson & Johnson decided to put its JLABS site outside of North America in Shanghai, Sanofi faces public uproar in the Philippines over Dengvaxia's safety issue, Astellas is taking full control of DMD expert Mitobridge, and more. [...]
Fri, Dec 08, 2017
Source FiercePharma
Novartis' Zykadia and AbbVie's Maviret get positive recommendations [...]
Fri, Dec 08, 2017
Source PharmaTimes
37 percent of patients had PFS for a year with Tecentriq and Avastin plus chemotherapy [...]
Fri, Dec 08, 2017
Source PharmaTimes
Could lead to "unparalleled" advances in the field [...]
Fri, Dec 08, 2017
Source PharmaTimes
More results may be out from a closely watched trial of Roche's Tecentriq in lung cancer, but industry watchers still don't have many of the answers they're looking for. [...]
Thu, Dec 07, 2017
Source FiercePharma
Novartis
Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), has commenced a cash tender offer to purchase all of the outstanding ordinary shares, nominal value EUR 0.10 per share, including Ordinary Shares [...]
Thu, Dec 07, 2017
Source WorldPharmaNews
Roche's Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for certain patients with metastatic urothelial carcinoma [...]
Thu, Dec 07, 2017
Source PharmaTimes
Sanofi
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia. [...]
Thu, Dec 07, 2017
Source WorldPharmaNews
A team of researchers led by the University of Minnesota has 3D printed lifelike artificial organ models that mimic the exact anatomical structure, mechanical properties, and look and feel of real organs. These patient-specific organ models, which include integrated soft sensors, can be used for practice surgeries to improve surgical [...]
Wed, Dec 06, 2017
Source WorldPharmaNews
Novo Nordisk
Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals. The global survey - Taking Diabetes to [...]
Wed, Dec 06, 2017
Source WorldPharmaNews
Thu, Nov 16, 2017
Source FDANews
An Alzheimer's research group offers positive news on clinical trials for Alzheimer's drugs as well as suggestions for the way forward, in a new report. [...]
Thu, Nov 16, 2017
Source FDANews
The FDA warned investigational medical device sponsor UVLrx Therapeutics for failing to obtain required authorization from its Institutional Review Board. [...]
Thu, Nov 16, 2017
Source FDANews
In a significant policy shift, China plans to accept data from foreign clinical trials in its drug approval process if the drug is already approved overseas. [...]
Thu, Nov 16, 2017
Source FDANews